Her medical history was significant for a diagnosis of SLE 3 years earlier, which was made on the basis of polyarthritis, pleurisy, hemolytic anemia, biopsy-proven WHO Class IV lupus nephritis ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

ALMS was a well-designed, randomized, controlled trial that included 370 patients with systemic lupus erythematosus (SLE) and class III, IV, or V nephritis. Like every recent major trial of new ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Conventional lupus nephritis (LN) treatment based on cyclophosphamide ... [1] It usually arises within 5–10 years of diagnosis and its prevalence varies depending on the population and the ...

The Phase 1 GALLOP study evaluating investigational therapy, CB-010, for treatment of lupus nephritis (LN) has officially started ... which is defined as lupus that is not characterized by Class ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

No writing assistance was utilized in the production of this manuscript. Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus. Immunological features ...